What Are Peptides? Therapeutic Uses, Mechanisms & Safety (2026 Guide)
A plain-language guide to peptide therapeutics – what they are, how clinicians use them, and how to think about safety, sourcing, and outcomes.
Quick answer
Peptides are short chains of amino acids—the same building blocks as proteins, just smaller—that bind specific cell-surface receptors to trigger targeted physiological signals like satiety, growth-hormone release, or tissue repair. Most therapeutic peptides are dispensed by Wells Pharmacy Network only after a licensed clinician evaluation; many are not FDA-approved as finished drug products.
Information presented for educational purposes only.
What is a peptide and how does it work?
Therapeutic peptides bind to specific receptors on the surface of cells, triggering a cascade of downstream effects. Because each peptide is highly selective for its target, side effects tend to be more limited than with broad-spectrum small molecules. Most therapeutic peptides are administered subcutaneously because the GI tract would otherwise digest them.
How do clinicians use Peptides?
How clinicians prescribe them
Peptide protocols are typically cycled – a defined course of weeks or months, paired with labs, lifestyle inputs, and clinician check-ins. The goal is to nudge a system back into balance, not to override it indefinitely.Sourcing and quality
Quality varies enormously across the peptide market. TexBioMed works only with 503A and 503B compounding pharmacies that meet our purity, potency, and chain-of-custody requirements.What to expect
Patient experience varies. Some adults inside a well-matched, clinician-directed protocol describe subtle, accumulating changes over the first several weeks; others do not. Lab markers and clinician check-ins are used to track response over time. No specific outcome is guaranteed.What are Peptides studied for?
Different peptides are studied in different research areas. The categories below summarise where the published literature is most active.
Recovery and tissue repair
BPC-157, TB-500, and GHK-Cu are studied in preclinical models of tendon, ligament, and connective-tissue healing. Clinicians often consider them as adjuncts in protocols framed around orthopedic recovery.
Growth-hormone axis support
GHRH analogues (CJC-1295, Tesamorelin) and GHRPs (Ipamorelin, GHRP-2/6) are studied for their effect on endogenous pulsatile GH release. This is a different mechanism than administering exogenous GH.
Metabolic and body-composition research
MOTS-c and AOD-9604 are studied for their effects on mitochondrial signalling and adipose-tissue lipolysis without raising IGF-1 in the same way as full-length GH.
Cognitive and neuroprotective research
Semax, Selank, Cerebrolysin, and Dihexa are studied for neurotrophic and neuroprotective signalling in the literature, primarily in animal models and small clinical observations.
Which compounds power Peptides protocols?
Wiki entries on individual compounds used inside Peptides protocols.
5-Amino-1MQ
A small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), studied for its effect on NAD+ recycling, fat metabolism, and metabolic-aging signaling.
AOD-9604
A 16-amino-acid fragment of human growth hormone studied for its effect on lipolysis without the broader anabolic signaling of full-length GH.
BPC-157
A 15-amino-acid sequence derived from a protein in human gastric juice, studied extensively in preclinical models for its effect on tendon, ligament, and gut mucosa repair.
CJC-1295
A growth-hormone-releasing-hormone (GHRH) analog studied for sustained stimulation of the body’s own pulsatile GH and IGF-1 release.
Dihexa
A small angiotensin IV-derived hexapeptide studied in preclinical models for hepatocyte growth factor (HGF) signaling and synaptogenesis in cognitive-aging research.
DSIP
A nine-amino-acid neuropeptide first isolated from rabbit cerebral venous blood, studied historically for sleep-modulating, stress-buffering, and analgesic effects.
Epithalon
A four-amino-acid bioregulator peptide developed in Russian gerontology research, studied for pineal-related sleep, melatonin rhythm, and telomerase signaling.
Follistatin
An endogenous glycoprotein that binds and neutralizes members of the TGF-β superfamily – including myostatin and activin – studied for muscle-mass and tissue-repair signaling.
FOXO4-DRI
A D-amino-acid retro-inverso peptide designed in 2017 to disrupt the interaction between FOXO4 and p53 in senescent cells.
GHK-Cu
A naturally occurring copper-binding tripeptide present in human plasma, studied for collagen signaling, wound healing, and skin-quality applications.
Gonadorelin
A short-chain analog of gonadotropin-releasing hormone that signals the pituitary to release LH and FSH.
Growth Hormone (GH)
A 191-amino-acid pituitary peptide hormone that drives linear growth in childhood and continues to support body composition, recovery, and metabolism in adulthood; recombinant forms (somatropin) are FDA-approved for specific deficiency states.
Humanin
A 24-amino-acid mitochondrial-derived peptide encoded within the 16S rRNA gene, studied for cytoprotective and metabolic-signaling effects.
IGF-1 LR3
A modified analog of insulin-like growth factor-1 with a longer half-life and reduced binding to IGF-binding proteins, studied historically in cell-culture research and in research-informed body-composition protocols.
Ipamorelin
A selective pentapeptide growth-hormone secretagogue (GHS-R agonist) studied for pituitary GH release without measurable cortisol or prolactin elevation.
Kisspeptin-10
A 10-amino-acid C-terminal fragment of kisspeptin that signals the hypothalamus to drive GnRH – and downstream LH and FSH – release.
KPV
A small C-terminal tripeptide of α-melanocyte-stimulating hormone studied for anti-inflammatory signaling in gut, skin, and oral-mucosal research.
LL-37
The only human cathelicidin antimicrobial peptide, a 37-amino-acid cationic peptide studied for antimicrobial, immunomodulatory, and wound-healing effects.
Melanotan II
A synthetic analog of α-melanocyte-stimulating hormone (α-MSH), studied for pigmentation effects via melanocortin receptors and historically the parent of bremelanotide (PT-141).
MOTS-c
A 16-amino-acid mitochondrial-derived peptide studied for its role in metabolic homeostasis, insulin sensitivity, and exercise capacity.
Oxytocin
A nine-amino-acid peptide hormone produced by the hypothalamus, studied for social-bonding signaling, stress modulation, and (commercially) for labor induction.
Pinealon
A short pineal-derived peptide bioregulator studied alongside Epithalon in Russian gerontology research for circadian and neuroprotective effects.
PT-141
A melanocortin-receptor agonist studied for central effects on sexual desire – distinct from PDE5 inhibitors that act on blood flow.
Selank
A synthetic heptapeptide analog of the endogenous immunomodulator tuftsin, originally developed in Russia and studied for anxiolytic and cognitive-modulation effects.
Semax
A short heptapeptide derived from a fragment of ACTH (4-7), studied in Russian neuroscience research for nootropic and neuroprotective effects.
SS-31
A mitochondrial-targeted peptide that binds cardiolipin on the inner mitochondrial membrane, studied for cellular-energy and cardiovascular research.
Synapsin
A neuronal phosphoprotein involved in synaptic-vesicle regulation; preparations under this name are used in clinician-directed nasal nootropic protocols often paired with Semax or NAD+.
Tesamorelin
A stabilized GHRH analog FDA-approved for HIV-associated lipodystrophy and studied for visceral-fat reduction in adults.
Thymosin Alpha-1
A 28-amino-acid peptide naturally produced by the thymus, studied as an immune modulator with a long international history in viral and oncology adjunct care.
Thymosin Beta-4
A 43-amino-acid actin-binding protein studied widely for tissue-repair, anti-inflammatory, and angiogenic signaling.
VIP
A 28-amino-acid neuropeptide with vasodilator, immunomodulatory, and circadian-signaling roles, studied in clinician-directed protocols for chronic inflammatory and post-viral indications.
Zinc Thymulin
A nonapeptide thymic hormone that requires zinc binding for activity, studied historically for immune-modulatory effects and topically for hair-loss research.
Frequently asked questions about Peptides
Are therapeutic peptides FDA-approved?
Some peptides have FDA-approved finished drug products under labeled indications (e.g. Tesamorelin for HIV-associated lipodystrophy, semaglutide for type 2 diabetes and chronic weight management). Most peptides discussed in research literature are not FDA-approved as finished drug products and, when used clinically, are accessed via 503A or 503B compounding pharmacies after an individual clinician evaluation.How do peptides differ from small-molecule drugs?
Peptides are short amino-acid chains that bind to specific cell-surface receptors. Small-molecule drugs are typically smaller, often cross the blood–brain barrier more readily, and frequently target intracellular enzymes. Because peptides are protein-based, they are usually given by subcutaneous injection rather than orally – the GI tract would otherwise digest them.How are peptide protocols designed?
A clinician reviews intake, history, and labs and decides whether a peptide is appropriate, which compound to consider, and at what dose, frequency, and cycle length. The clinician also defines the monitoring plan: which labs are repeated, how often, and what markers count as a stop signal.What are the most common side effects?
Side effects depend on the specific peptide. Common categories include local injection-site reactions, transient water retention with GH-axis peptides, and flushing with histaminergic peptides such as PT-141. Any reproducibly tolerated protocol is the result of clinician-directed dose titration.Is purity a real concern?
Yes. The peptide market includes a wide range of grey-market vendors with no enforceable purity standard. TexBioMed works only with 503A and 503B compounding pharmacies that meet our purity, potency, and chain-of-custody requirements, and the dispensing pharmacy is named for every prescription.Can I combine peptides?
Combination protocols (e.g. CJC-1295 with Ipamorelin, BPC-157 with TB-500) are common in the literature, but combinations should always be designed by the prescribing clinician. Stacking peptides without supervision risks unbalancing the same axes the protocol is meant to support.Where can I read the source research?
Sikiric P et al. – BPC-157 in tendon, ligament, and gut research (multiple reviews)
Teichman SL et al., J Clin Endocrinol Metab 2006 – CJC-1295 sustained GH/IGF-1 elevation
Lee C et al., Cell Metab 2015 – MOTS-c regulates insulin sensitivity and metabolic homeostasis
FDA – Compounding and the FDA: Questions and answers (503A vs. 503B)
Research and clinical use
Compounds discussed on this page are intended for laboratory and clinical research only. They are not approved by the FDA for human use outside of an authorized clinical context. This page is informational and is not medical advice. Always speak with a qualified clinician before starting, stopping, or changing any therapy.